Stock APPH APONTIS PHARMA AG
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Apontis Pharma AG

Equities

APPH

DE000A3CMGM5

Real-time Estimate Tradegate
Other stock markets
 06:05:43 2024-05-29 EDT 		5-day change 1st Jan Change
8.17 EUR -2.51% Intraday chart for Apontis Pharma AG -10.13% +71.79%
04-05 Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications MT
03-28 Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DD: APONTIS PHARMA AG: Thomas Milz, buy
EQ
DD: APONTIS PHARMA AG: be executive GmbH, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
Apontis Pharma : Earnings Call Q1/24 Presentation
PU
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQ
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQ
APONTIS PHARMA expects profitable growth again in 2024
EQ
Apontis Pharma : Earnings Call 2023 Presentation
PU
APONTIS PHARMA successfully completes performance and efficiency improvement program
EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
EQ
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
EQ
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline
EQ
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched
EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APPH Stock
  4. News Apontis Pharma AG
  5. Press Releases